NASDAQ: BDMDBaird Medical Investment Holdings Ltd Stock
$2.45-0.07 (-2.78%)
Updated Nov 29, 2024
BDMD Price
$2.45
Fair Value Price
N/A
Market Cap
$16.13M
52 Week Low
$1.80
52 Week High
$13.52
P/E
-4.54x
P/B
-1.14x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$4.88M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.06
Operating Cash Flow
-$2M
Beta
0.04
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BDMD Overview
ExcelFin Acquisition Corporation was formed to effect mergers, capital stock exchanges, asset acquisitions, stock purchases, reorganizations, or similar combinations with one or more businesses. The commpany intends to focus on a U.S.-domiciled FinTechs in the business-to-business and software-as-a-service sectors.The company was incorporated in 2021 and is based in San Francisco, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BDMD's potential to beat the market
- BDMD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
BDMD
RankedUnranked of 90
RankedUnranked of 90
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $30.78 | A | |
| $12.29 | A | |
| $19.54 | A |
Be the first to know about important BDMD news, forecast changes, insider trades & much more!
BDMD News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BDMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BDMD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BDMD is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
BDMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more BDMD due diligence checks available for Premium users.
Valuation
BDMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.54x
Industry
37.55x
Market
27.74x
BDMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.14x
Industry
4.13x
BDMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$858.7k
Profit Margin
0%
BDMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$17.5M
Liabilities
$15.0M
Debt to equity
-1.06
BDMD's short-term liabilities ($13.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BDMD's long-term liabilities ($1.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BDMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BDMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$780.8k
Investing
$7.5M
Financing
-$7.2M
BDMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BDMD vs Medical Device Stocks
Baird Medical Investment Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.